References

1.     Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001;42:1551–5.

2.     Durack DT, Street AC. Fever of unknown origin–reexamined and redefined. Current Clinical Topics in Infectious Diseases 1991;11:35–51

3.     Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund KÅ, et al. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances. Ann ICRP 2015;44:7–321. https://doi.org/10.1177/0146645314558019.

4.     Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. European Journal of Nuclear Medicine and Molecular Imaging 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x.

5.     The Royal College of Radiologists, Royal College of Physicians, British Nuclear Medicine Society, Administration of Radioactive Substances Advisory Committee. Evidencebased indications for the use of PET-CT in the United Kingdom 2022. London: The Royal College of Radiologists, 2022.

6.     Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT in infection and inflammation—current and emerging clinical applications. Clinical Radiology 2015;70:787–800. https://doi.org/10.1016/j.crad.2015.03.010.

7.     Arnon-Sheleg E, Israel O, Keidar Z. PET/CT Imaging in Soft Tissue Infection and Inflammation-An Update. Semin Nucl Med 2020;50:35–49. https://doi.org/10.1053/j.semnuclmed.2019.07.005.

8.     Webb RL, Landau E, Klein D, DiPoce J, Volkin D, Belman J, et al. Effects of varying serum glucose levels on 18F-FDG biodistribution. Nucl Med Commun 2015;36:717–21. https://doi.org/10.1097/MNM.0000000000000319.

9.     Pijl JP, Glaudemans AWJM, Gheysens O, Slart RHJA, Kwee TC. Importance of Blood Glucose Management Before 18F-FDG PET/CT in 322 Patients with Bacteremia of Unknown Origin. Journal of Nuclear Medicine. 2023;64:1287–94.

10.     Hess S, Scholtens AM, Gormsen LC. Patient Preparation and Patient-related Challenges with FDG-PET/CT in Infectious and Inflammatory Disease. PET Clin 2020;15:125–34. https://doi.org/10.1016/j.cpet.2019.11.001.

11.     Scholtens AM, van den Berk AM, van der Sluis NL, Esser JP, Lammers GK, de Klerk JMH, et al. Suppression of myocardial glucose metabolism in FDG PET/CT: impact of dose variation in heparin bolus pre-administration. Eur J Nucl Med Mol Imaging 2020. https://doi.org/10.1007/s00259-020-04713-1.

12.    Slart RHJA, Slart RHJA, Glaudemans AWJM, Chareonthaitawee P, Treglia G, Besson FL, et al. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging 2018;45:1250–69. https://doi.org/10.1007/s00259-018-3973-8.

13.     Abikhzer, G., Treglia, G., Pelletier-Galarneau, M. et al. EANM/SNMMI guideline/procedure standard for [18F]FDG hybrid PET use in infection and inflammation in adults v2.0. Eur J Nucl Med Mol Imaging 52, 510–538 (2025). https://doi.org/10.1007/s00259-024-06915-3

14.     ICRP. ICRP Publication 80. Radiation Dose to Patients from Radiopharmaceuticals: A Compendium of Current Information Related to Frequently Used Substances. Annals ICRP 1998;28.

15.     ICRP. ICRP Publication 53. Radiation dose to patients from radiopharmaceuticals. Annals ICRP 1988;18.

16.     Signore A, Jamar F, Israel O, Buscombe J, Martin-Comin J, Lazzeri E. Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline. Eur J Nucl Med Mol Imaging 2018;45:1816–31. https://doi.org/10.1007/s00259-018-4052-x.

17.     Roca M, De Vries EFJ, Jamar F, Israel O, Signore A, Roca M, et al. Guidelines for the labelling of leucocytes with 111 In-oxine. Eur J Nucl Med Mol Imaging 2010;37:835–841. https://doi.org/10.1007/s00259-010-1394-5.

18.     De Vries EFJ, Roca M, Jamar F, Israel O, Signore A, De Vries EFJ, et al. Guidelines for the labelling of leucocytes with 99m Tc-HMPAO. Eur J Nucl Med Mol Imaging 2010;37:842–848. https://doi.org/10.1007/s00259-010-1394-4.

19.     Gratz S, Reize P, Kemke B, Kampen WU, Luster M, Höffken H. Targeting osteomyelitis with complete [99mTc]besilesomab and fragmented [99mTc]sulesomab antibodies: kinetic evaluations. Q J Nucl Med Mol Imaging 2016;60:413–23.

20.     Meller J, Liersch T, Oezerden MM, Sahlmann CO, Meller B. Targeting NCA-95 and other granulocyte antigens and receptors with radiolabeled monoclonal antibodies (Mabs). Q J Nucl Med Mol Imaging 2010;54:582–98.

21.     Xing D, Ma X, Ma J, Wang J, Chen Y, Yang Y. Use of anti-granulocyte scintigraphy with 99mTc-labeled monoclonal antibodies for the diagnosis of periprosthetic infection in patients after total joint arthroplasty: a diagnostic meta-analysis. PLoS ONE 2013;8:e69857. https://doi.org/10.1371/journal.pone.0069857.

22.     Wang G, Zhao K, Liu Z, Dong M, Yang S. A meta-analysis of fluorodeoxyglucose-positron emission tomography versus scintigraphy in the evaluation of suspected osteomyelitis. Nucl Med Commun 2011;32:1134–42. https://doi.org/10.1097/MNM.0b013e32834b455c.

23.     European Medicines Agency. LeukoScan. European Medicines Agency 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/leukoscan (accessed July 20, 2020).

24.     European Medicines Agency. Scintimun. European Medicines Agency 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/scintimun (accessed July 20, 2020).

25.     Dickson J, Eberlein U, Lassmann M. The effect of modern PET technology and techniques on the EANM paediatric dosage card. European Journal of Nuclear Medicine and Molecular Imaging. 2022;49(6):1964-1969. DOI: 10.1007/s00259-021-05635-2.